Conner C S
Drug Intell Clin Pharm. 1985 Jun;19(6):475-6. doi: 10.1177/106002808501900612.
Numerous beta-lactamase inhibitors have been developed to overcome the problems of bacterial resistance to beta-lactam antibiotics. One such agent, clavulanic acid, has been combined with amoxicillin, and the combination is effective against many amoxicillin-resistant organisms. Clinical studies have demonstrated the efficacy of amoxicillin/clavulanate in a variety of infections, however, comparative studies are few and have not demonstrated sufficiently the superiority of the combination over conventional antibiotic therapy. In addition, side effects appear to be more frequent than with amoxicillin alone. The place in therapy of amoxicillin/clavulanate is discussed.
为克服细菌对β-内酰胺类抗生素耐药的问题,人们已研发出多种β-内酰胺酶抑制剂。其中一种药物,克拉维酸,已与阿莫西林联合使用,该组合对许多耐阿莫西林的微生物有效。临床研究已证明阿莫西林/克拉维酸在多种感染中的疗效,然而,对比研究较少,且尚未充分证明该组合优于传统抗生素疗法。此外,副作用似乎比单独使用阿莫西林时更频繁。本文讨论了阿莫西林/克拉维酸在治疗中的地位。